IndustryCompany release
Lakefront Biotherapeutics launches second €50m share buyback after completing first programme
Lakefront Biotherapeutics · Mon 16 Nov 2026
The Euronext- and NASDAQ-listed company will repurchase up to €50 million of its own shares through Morgan Stanley, with the programme running to 31 March 2027 at the latest.
Lakefront Biotherapeutics NV (Euronext and NASDAQ: LKFT) announced on 16 November 2026 a new share buyback of up to €50 million, or up to 4,604,550 shares. The programme will run until 31 March 2027 at the latest.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release: Lakefront Biotherapeutics ↗
Article written by VigiEye from the official source (Lakefront Biotherapeutics). Claims are the company's own. AI-assisted; check the source before acting.
More Industry
All →
Merck KGaA to acquire Rapid Micro Biosystems; Q3 revenue rises to $9.5M
🇺🇸 Rapid Micro Biosystems, Inc. (RPID) · Mon 16 Nov 2026
Microbot Medical Q3 revenue falls to $72,000 as gross margin turns negative
🇺🇸 Microbot Medical Inc. (MBOT) · Mon 16 Nov 2026
TOYO Co. reports lower Q3 revenue and net income, but higher nine-month sales
TOYO Co., Ltd (TOYO) · Mon 16 Nov 2026
Eocene unit and Barcode Nanotech develop tumour-targeted nanoparticle form of Aramchol for liver and GI cancers
EoCene Ltd. (EOCN) · Mon 16 Nov 2026
Corbus starts registrational TEMPO-1 trial of Nectin-4 ADC sutantatug envedotin in OPSCC
🇺🇸 Corbus Pharmaceuticals Holdings, Inc. (CRBP) · Mon 16 Nov 2026
Adagio Medical's VT ablation PMA remains under FDA review as board explores strategic alternatives
🇺🇸 Adagio Medical Holdings, Inc. (ADGM) · Mon 16 Nov 2026